Bragar Eagel &amp; Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options  If you purchased or acquired

ALDX

Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th

Class Action Lawsuit Filed Against Aldeyra Therapeutics Over Misleading Claims

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Bragar Eagel &amp;amp; Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options  If you purchased or acquired</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>A class action lawsuit has been filed against Aldeyra Therapeutics for allegedly misleading investors about the efficacy of reproxalap clinical trials. Investors have until May 29, 2026, to join the lawsuit, which could impact ALDX&#039;s reputation and stock performance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Class action lawsuit filed against ALDX for misleading statements.</li><li>Allegations include inconsistent clinical trial results for reproxalap.</li><li>Investors can apply as lead plaintiffs by May 29, 2026.</li><li>Losses reported by investors during class period from Nov 2023 to Mar 2026.</li><li>Law firm encourages affected investors to seek legal recourse.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Aldeyra Therapeutics, Inc. (ALDX)</strong>: Facing significant litigation risks affecting its credibility.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This situation falls under &#039;Legal&#039; due to the class action lawsuit that could impact investor confidence and the company&#039;s stock price.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Inconsistent clinical trial results could undermine ALDX&#039;s future drug approvals.</li><li>Potential for negative sentiment as investors react to lawsuit developments.</li><li>Legal proceedings may delay ALDX&#039;s market strategies and product launches.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Lawsuit filed in U.S. District Court for Massachusetts.</li><li>Class period for alleged violations: November 3, 2023, to March 16, 2026.</li><li>Investors have until May 29, 2026, to apply as lead plaintiffs.</li><li>ALDX accused of issuing false statements about clinical trials.</li><li>Results of reproxalap trials deemed inconsistent and unreliable.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting ALDX in the near term due to legal risks.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify"><strong>Bragar Eagel &amp; Squire, P.C. </strong><strong>Litigation Partner </strong><a href="https://www.globenewswire.com/Tracker?data=VgykZvtymn1rAF8jR--2l61NfOPEhr7ReUC45ugj9_47KFKrjkK3lXFxLXKWXxlT4fjdVKoajAkVOChMelrjtpD9DWMnb4rAhEt49JdzPqLUG0HUq5PUnAzPRQX5A8nY" rel="nofollow" target="_blank"><strong>Brandon Walker</strong></a><strong> Encourages Investors Who Suffered Losses In Aldeyra (ALDX) To Contact Him Directly To Discuss Their Options</strong></p>  <p align="justify"><strong>If you purchased or acquired Aldeyra securities between November 3, 2023 and March 16, 2026 and would like to discuss your legal rights, call Bragar Eagel &amp; Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648.</strong></p>  <p align="justify">Click <a href="https://www.globenewswire.com/Tracker?data=4OlMdJAsesaHOVy5XKRVoHIhT4lr9Vm3jcPJ1zag_XlTixZOFZSvh94xyE4omxlPZf-C-1_fFlYhBIIsx-p3hg==" rel="nofollow" target="_blank">here</a> to participate in the action.</p>  <p align="justify">NEW YORK, May  11, 2026  (GLOBE NEWSWIRE) -- </p>  <p align="justify"><strong>What's Happening?</strong></p>  <ul type="circle"><li style="margin-bottom:12pt; text-align:justify;"><a href="https://www.bespc.com" rel="nofollow" target="_blank">Bragar Eagel &amp; Squire, P.C</a>., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ALDX">ALDX</a>) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Aldeyra securities between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period"). Investors have until May 29, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit.<br></br><br></br></li></ul>  <p align="justify"><strong>What are the Allegation Details?</strong></p>  <ul type="circle"><li style="text-align:justify;">The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Aldeyra's business, operations, and prospects, including allegations that: (1) the results of the reproxalap clinical trials were inconsistent; and (2) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful.<br></br><br></br></li></ul>  <p align="justify"><strong>What are the Next Steps?</strong></p>  <ul type="circle"><li style="text-align:justify;">If you purchased or otherwise acquired Aldeyra shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact <a href="https://www.bespc.com/professionals/brandon-walker" rel="nofollow" target="_blank">Brandon Walker</a> or <a href="https://www.bespc.com/professionals/melissa-fortunato" rel="nofollow" target="_blank">Melissa Fortunato</a> by email at <a href="mailto:investigations@bespc.com" rel="nofollow" target="_blank">investigations@bespc.com</a>, telephone at (212) 355-4648, or by <a href="https://bespc.com/cases/ALDX" rel="nofollow" target="_blank">filling out this contact form</a>. There is no cost or obligation to you.<br></br><br></br></li></ul>  <p><strong>About Bragar Eagel &amp; Squire, P.C.:</strong></p>  <p align="justify">Bragar Eagel &amp; Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California. The firm represents individual and institutional investors in securities, derivative, and commercial litigation as well as individuals in consumer protection and data privacy litigation. The firm has a nationwide practice and routinely handles cases in both federal and state courts. For more information about the firm, please visit <a href="https://www.globenewswire.com/Tracker?data=3ljt0lYfeVprxtvUNC6ikdxkA-f24N5PcxuI_Y2ONjXD2iFVwnWb8rcUixHFZRvsUCb4ZwfHNE0T_GiELfdF2A==" rel="nofollow" target="_blank">www.bespc.com</a>.  Attorney advertising.  Prior results do not guarantee similar outcomes.</p>  <p align="justify">Follow us for updates on <a href="https://www.globenewswire.com/Tracker?data=L0Jnm7H1W9iphr4xCj8AePWH_rxzLOQkHfSybetGgmtDvOdR0llHMFNlz6UFuJEyr72itRTJ0bAxYH4ZuOw9Iwx843ODnVvobtMgFm5QzPX_rSatqDiHYLENvj58T8Jx" rel="nofollow" target="_blank">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=wUojpaGl29T4ec2TiXHvFW9CklAg3jjL6rhXwgfFKHIISARdR7gfH-UZ5RmgdG_c-fEh-kiQNbDSYuk4zyK7ZkU8fFVVYqyoKrTla1QTSXFTdPldx50nhDdkhOqoRYpY" rel="nofollow" target="_blank">Facebook</a>, and keep up with other news by following Brandon Walker, Esq. on <a href="https://www.globenewswire.com/Tracker?data=L0Jnm7H1W9iphr4xCj8AeOjftMIhtnW_u9cUKEuYOv3vNjmEb97wjb52DHoBfehj7aWo1P-u1u8Hrg6oRhtN4574MV5nc3p8yEkmInFN2-2n-G-DSIrd-XZtXGhG-wuq" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Contact Information:</strong></p>  <p>Bragar Eagel &amp; Squire, P.C.<br></br>Brandon Walker, Esq.<br></br>Melissa Fortunato, Esq.<br></br>(212) 355-4648<br></br><a href="https://www.globenewswire.com/Tracker?data=iehmR96u8UrlHLT4ClRihk8397iznTvMO86UeAfX10Hy0z4N3Wcuiy1NuvEY8TK39Pdf8qL9pQ9nfIlWXatIAxJTtLCRZwgbOhTEm-Eea7hMBtnBTc-_X_NvaAEs0ozc" rel="nofollow" target="_blank"><u>investigations@bespc.com</u></a><br></br><a href="https://www.globenewswire.com/Tracker?data=3ljt0lYfeVprxtvUNC6ikVoyoNr3OBp0VOqplrsw8XWoHZRBhrra1IoXPMiXtCpIKzZhqlxJ2EgWSWWx7hxpyQ==" rel="nofollow" target="_blank"><u>www.bespc.com</u></a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxODAyMiM3NTk3MDU3IzIxMDAzOTg="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NjJmYTQ0N2YtZjU1Mi00NjUyLWE5YjMtMGNiZWI2MzViYzYyLTExMTE5NjktMjAyNi0wNS0xMi1lbg==/tiny/Bragar-Eagel-Squire.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/29481954-f2ff-4756-b5a9-d982a6497bd0"><img src="https://ml.globenewswire.com/media/29481954-f2ff-4756-b5a9-d982a6497bd0/small/bes-mark-jpg.jpg" border="0" width="150" height="75" alt="Primary Logo"></img></a></p>

A class action lawsuit has been filed against Aldeyra Therapeutics for allegedly misleading investors about the efficacy of reproxalap clinical trials. Investors have until May 29, 2026, to join the lawsuit, which could impact ALDX's reputation and stock performance.

Bragar Eagel & Squire, P.C. Encourages Aldeyra Therapeutics, Inc. Investors with Large Losses to Contact the Firm Regarding Their Rights Before May 29th

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News